Clinical trials: Clinical High-risk
Coronary Artery Disease, Heart Failure
Clinical Trial of Ventiflow LP Supporting High-risk Percutaneous Coronary Intervention(PCI)
The purpose of this prospective, multicenter, randomized controlled clinical trial is to evaluate the effectiveness of the transcatheter left ventricular assist system (Ventiflow LP) in providing circulatory support to patients…
- Conditions
- Coronary Artery Disease, Heart Failure, High-risk PCI
- Trial name
- NCT06754839
- Testing
- Percutaneous left ventricular assist device(Ventiflow LP), VA-ECMO
- Volunteers
- 250 people
- Sponsor
- Suzhou Hearthill Medical Technology Co.,LTD
Respiratory Failure
Optiflow in Sequential Non-Invasive Ventilation
Background : Patient with hypoxemic respiratory failure treated with NIV receive between NIV session oxygen therapy. Gaz exchange disorder with a decrease of the ratio between Partial Pressure of Arterial Oxygen (PaO2) and…
- Trial name
- VNI-HD (NCT02389166)
- Testing
- Optiflow, Conventional oxygen therapy
- Where
- 8 sites in France
- Volunteers
- 95 people
- Sponsor
- University Hospital, Bordeaux
Dyslipidemia
Dyslipidemia in Cardiovascular Disease
A multi-center, randomized, double-blinded equivalence clinical trial to evaluate efficacy and safety of LipiLou 20 mg versus Lipitor 20 mg in hypercholesterolemic patients with higher risk cardiovascular disease in Korea.
- Trial name
- KoLipilou (NCT01029522)
- Testing
- Atorvastatin (Lipilou), Atorvastatin (Lipitor)
- Volunteers
- 244 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Newly Diagnosed Secondary or High Risk AML
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
This protocol corresponds to a prospective, multicentre, open label, phase II study designed to evaluate the efficacy of CPX-351 in elderly patients with secondary or high-risk AML.
- Trial name
- LAMVYX (NCT04230239)
- Testing
- CPX-351
- Where
- 12 sites in Spain
- Volunteers
- 59 people
- Sponsor
- PETHEMA Foundation
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cervical Carcinoma
Clinical Validation of Molecular Triage in HR-HPV Positive Women
Women accessing the HPV-based screening programme for primary screening, will undergo cervical sampling and clinical data recording.
- Trial name
- VALTRIHP (NCT05193669)
- Where
- Italy
- Volunteers
- 23,941 people
- Sponsor
- Hiantis Srl
Non-muscle-invasive Bladder Cancer
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
For patients with high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical therapy of BCG is the standard treatment proved to reduce the risk of recurrence and progression.
- Trial name
- NCT05580354
- Testing
- BCG combined with Tislelizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ruijin Hospital
Bladder Cancer
Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
This is a single-center, prospective, open-label, non-randomized clinical study initiated and conducted by the Department of Urology, Shanghai Changhai Hospital.
- Trial name
- MARINE-01 (NCT07307456)
- Testing
- Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Changhai Hospital
Hypertension, Stroke
Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension
The purpose of this study is to compare the effect of cilnidipine (a calcium channel blocker) and losartan (an angiotensin II receptor blocker) on cerebral blood flow (CBF) and blood pressure in hypertensive patients with a…
- Trial name
- NCT00325637
- Testing
- cilnidipine
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
Resectable Non-small Cell Lung Cancer, Bispecific Antibody
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
The advent of immunotherapy has changed the treatment landscape for patients with non-small cell lung cancer. It has become the mainstay of perioperative treatment for patients with resectable non-small cell lung cancer。…
- Conditions
- Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
- Trial name
- Neoadjuvant (NCT06946836)
- Testing
- AK104
- Volunteers
- 80 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Diffuse Large B Cell Lymphoma
Chidamide With R-CHOP Regimen for DLBCL Patients
It's a prospective, single arm, open label phase II clinical trial, in which the safety and efficacy of Chidamide plus R-CHOP regimen is accessed in de novo DLBCL patients, who have received 2 courses of R-CHOP but only achieved…
- Trial name
- DLBCL (NCT03201471)
- Testing
- Chidamide + R-CHOP regimen
- Where
- China
- Volunteers
- 39 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hemodynamic (MAP) Stability, Fluid Management
Hemodynamic Optimization Using an Artificial Intelligenze System
This study will investigate the impact of using an automated fluid management system on intraoperative fluid therapy in patients undergoing colorectal surgery.
- Trial name
- SIMPLY (NCT07366164)
- Testing
- assisted fluid therapy
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Corneal Transplantation
Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty
Because of the immunologically privileged nature of the cornea, the graft rejection rate is less than 10% for low-risk keratoplasty.
- Trial name
- NCT04490902
- Testing
- Limbal transplantation combined with central penetrating keratoplasty
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg
Covid19, Corona Virus Infection
Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients
Vitamin D is a secosteroid hormone which may have beneficial role in reducing COVID-19 adverse outcomes by first regulating the renin angiotensin system (RAS).
- Conditions
- Covid19, Corona Virus Infection, Cytokine Storm, Vitamin D Deficiency
- Trial name
- NCT04738760
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Ain Shams University
Coarctation of Aorta, High Blood Pressure
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.
- Trial name
- VALUE (NCT06150560)
- Testing
- Losartan, Amlodipine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
High Caries Risk Patients, Antimicrobial Effect
Antibacterial Effect of Guava Leaves Extract Mouthwash Compared to Chlorhexidine Mouthwash in High Caries Risk Patients
This trial is to test the antibacterial effect of Guava leaves extract mouth wash compared to Chlorhexidine mouth wash in high caries risk patients. Also salivary pH and patient satisfaction to taste will also be tested.
- Conditions
- High Caries Risk Patients, Antimicrobial Effect, Salivary pH, Patient Satisfaction to Taste
- Trial name
- NCT03773094
- Testing
- Guava leaves extract, Chlorhexidine
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Cairo University
Carcinoma, Hepatocellular
Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients
This study aims to evaluate the effectiveness of radiotherapy before surgery in high-risk relapse hepatocellular cancer patients.
- Trial name
- NCT02580929
- Testing
- radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.